Related Experiment Videos
Topically applied erythromycin in inflammatory acne vulgaris
Journal of the American Academy of Dermatology
|April 1, 1980
Summary
This study found that 2% erythromycin significantly reduced inflammatory acne vulgaris lesions compared to its vehicle. Erythromycin also demonstrated a lower adverse reaction rate, possibly due to its anti-inflammatory effects.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Acne vulgaris is a common inflammatory skin condition.
- Topical treatments are a cornerstone of acne vulgaris management.
Purpose of the Study:
- To evaluate the efficacy of 2% erythromycin versus its vehicle in treating inflammatory acne vulgaris.
- To assess the safety and tolerability profile of topical erythromycin.
Main Methods:
- A clinical trial involving 348 patients with inflammatory acne vulgaris.
- Comparison of lesion counts (papulopustules) between erythromycin and vehicle groups.
- Physician global ratings assessed overall clinical improvement.
Main Results:
- Erythromycin treatment led to a significantly greater reduction in papulopustule count.
- Physician global ratings indicated significantly better clinical improvement with erythromycin.
- The erythromycin group exhibited a lower rate of adverse reactions.
Conclusions:
- 2% topical erythromycin is effective in reducing inflammatory acne vulgaris.
- Erythromycin's anti-inflammatory properties may contribute to its favorable safety profile in acne treatment.